Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | LPL | P06858 | 5/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.43 |
| ▸ | F11 | P03951 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801560 | 0.90 | ROCK1 (0.44) | ROCK1LPLLIPGF11SMN1; SMN2 | |
| SCHEMBL2800935 | 0.87 | MAPT (0.56) | ROCK1LPLLIPGF11SMN1; SMN2 | |
| SCHEMBL578532 | 0.85 | MAPT (0.56) | ROCK1LPLLIPGF11SMN1; SMN2 | |
| SCHEMBL17619412 | 0.82 | HSD11B1 (0.59) | ROCK1LPLLIPGF11SMN1; SMN2 | |
| SCHEMBL2826100 | 0.82 | ROCK1 (0.69) | ROCK1LPLLIPGF11MAPT | |
| SCHEMBL15879483 | 0.79 | ROCK1 (0.68) | ROCK1LPLLIPGF11F2 | |
| SCHEMBL22233270 | 0.78 | ALDH1A1 (0.47) | ROCK1LPLLIPGSMN1; SMN2MEN1 | |
| SCHEMBL9888312 | 0.75 | SMN1; SMN2 (0.37) | SMN1; SMN2MAPTNPC1HPGDMEN1 | |
| SCHEMBL2798346 | 0.74 | SMN1; SMN2 (0.69) | SMN1; SMN2MAPTNPC1HPGDMEN1 | |
| SCHEMBL4478572 | 0.73 | LIPG (0.57) | LPLLIPGF11F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | ROCK1 205/4885LPL 4859/4885LIPG 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.